Niki BioSolutions COO receives 80,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Niki BioSolutions, Inc. President & COO Alidad Mireskandari received 20,000 restricted stock units that vested on July 22, 2026, and reported 20,000 common shares following the transaction. He also received 80,000 stock options with an $8.83 exercise price, expiring July 22, 2036. The options vest through quarterly installments and specified milestones tied to revenue, financing, agreements, a clinical validation study, and stock-price performance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units F1, F2 | 20,000 | $0.00 | $0.00 |
| Grant/Award | Stock Options F3 | 80,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 20,000 | -- | -- |
Footnotes (3)
- F1. Each RSU represents a contingent right to receive, upon settlement, one share of Common Stock.
- F2. On July 22, 2026, the reporting person was granted 20,000 RSUs, which vested on that same date.
- F3. The options vest as follows: (i) 40,000 options vest in eight equal quarterly installments; (ii) 5,000 options vest upon completion and publication of the clinical validation study of CogniMIR(R) to meet CLIA requirements; (iii) 10,000 options vest upon the Company entering into a biopharmaceutical services, collaboration or partnership agreement resulting in proceeds to the Company of at least $250,000; (iv) 5,000 options vest upon the Company generating $1,000,000 in revenue; (v) 10,000 options vest upon completion of capital raises totaling $5,000,000; and (vi) 10,000 options vest upon a 100% increase in the Company's stock price following the closing of the merger that occurred in July 2026.
Key Figures
Key Terms
RSU technical
stock options financial
vest technical
clinical validation study medical
CLIA requirements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did NIKI's President & COO receive?
How do the NIKI stock options vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.